Antigenicity analysis of human parvovirus B19-VP1u protein in the induction of anti-phospholipid syndrome

Virulence. 2018 Jan 1;9(1):208-216. doi: 10.1080/21505594.2017.1385691. Epub 2017 Nov 30.

Abstract

Mounting evidence suggests a connection between human parvovirus B19 (B19) and autoimmune diseases, and especially an association between the B19-VP1 unique region (VP1u) and anti-phospholipid syndrome (APS). However, little is known about the antigenicity of B19-VP1u in the induction of APS-like syndrome. To elucidate the antigenicity of B19-VP1u in the induction of APS, N-terminal truncated B19-VP1u (tVP1u) proteins were prepared to immunize Balb/c mice to generate antibodies against B19-tVP1u proteins. The secreted phospholipase A2 (sPLA2) activities and binding specificity of mice anti-B19-tVP1u antibodies with cardiolipin (CL) and beta-2-glycoprotein I (β2GPI) were evaluated by performing immunoblot, ELISA and absorption experiments. A mice model of passively induced APS was adopted. Although sPLA2 activities were identified in all B19-tVP1u proteins, only amino acid residues 61-227 B19-tVP1u exhibited a higher sPLA2 activity. Autoantibodies against CL and β2GPI exhibited binding activities with all B19-tVP1u proteins. IgG that was purified from mice that had been immunized with amino acid residues 21-227 to 121-227 B19-tVP1u proteins exhibited significantly higher binding activity with CL. IgG that was purified from mice that had been immunized with amino acid residues 21-227, 31-227, 82-227 and 91-227 B19-tVP1u proteins exhibited significantly higher binding activity with β2GPI. Accordingly, significantly higher binding inhibition of CL was detected in the presence of amino acid residues 61-227 and 101-227 B19-tVP1u. Significantly higher binding inhibition of β2GPI was detected in the presence of amino acid residues 21-227, 31-227, 82-227 and 91-227 B19-tVP1u. The mice that received amino acid residues 31-227 or 61-227 anti-tB19-VP1u IgG revealed significant thrombocytopenia and those that received amino acid residues 21-227, 31-227, 61-227, 71-227, 82-227, 91-227, 101-227 or 114-227 anti-tB19-VP1u IgG exhibited significantly prolonged aPTT. These findings provide further information concerning the role of B19-VP1u antigenicity in APS-like autoimmunity.

Keywords: Anti-phospholipid syndrome-like (APS-like); VP1 unique region protein (VP1u); beta2-glycoprotein I (β2GPI); cardiolipin (CL); human parvovirus B19 (B19).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiphospholipid Syndrome / immunology*
  • Autoantigens / metabolism
  • Capsid Proteins / antagonists & inhibitors
  • Capsid Proteins / chemistry*
  • Capsid Proteins / immunology*
  • Cardiolipins / metabolism
  • Disease Models, Animal
  • Female
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Immunoglobulin G / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Parvovirus B19, Human / immunology*
  • Phospholipases A2, Secretory / analysis
  • Protein Binding
  • beta 2-Glycoprotein I / metabolism

Substances

  • Autoantigens
  • Capsid Proteins
  • Cardiolipins
  • Immunoglobulin G
  • beta 2-Glycoprotein I
  • capsid protein VP1, parvovirus B19
  • Phospholipases A2, Secretory

Grants and funding

The authors would like to thank the Ministry of Science and Technology of the Republic of China, Taiwan, for financially supporting this research under Contract No. MOST 105-2314-B040-020 and NSC 98–2314-B-040–008-MY3, NSC101-2314-B-040-008 and the Chung Shan Medical University and Chi-Mei Medical Center cooperative project [CSMU-CMMC-103-03], Taiwan.